<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626765</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-T for Childhood B-ALL</org_study_id>
    <nct_id>NCT04626765</nct_id>
  </id_info>
  <brief_title>CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia</brief_title>
  <official_title>An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Children With Relapsed and Refractory Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, CAR-T will be administered to children with acute lymphoblastic leukemia to&#xD;
      explore the effect of CAR-T intervention time on the duration of complete remission and&#xD;
      further verify the long-term safety and efficacy of CAR-T treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After clinician evaluation, if the child meets the study criteria and after adequate&#xD;
      communication, the parent or legal guardian voluntarily joins the clinical study, CAR-T&#xD;
      technique can be used for related treatment, and the long-term therapeutic effect can be&#xD;
      observed. In this trial, 50 children were publicly enrolled and treated with CAR-T. Patients&#xD;
      participating in the clinical trial will be tested and assessed in terms of treatment safety,&#xD;
      efficacy, and duration of response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Severe/Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Number of Participants with Severe/Adverse Events as a Measure of Safety diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAR-T Cell expansion level</measure>
    <time_frame>24 months</time_frame>
    <description>Copies numbers of CAR in peripheral blood(PB) and/or bone marrow(BM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate of complete remission and partial remission</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response rate of complete remission and partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>volunteer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The child's parents or legal guardians voluntarily signed the informed consent form, and the child himself/herself met the enter criteria for the diagnosis of patients with acute B-lymphoblastic leukemia (B-ALL) expressing specific target antigens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD19 CAR-T</intervention_name>
    <description>CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells</description>
    <arm_group_label>volunteer</arm_group_label>
    <other_name>Senl_19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD22 CAR-T</intervention_name>
    <description>CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells</description>
    <arm_group_label>volunteer</arm_group_label>
    <other_name>Senl_22</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD 19+22</intervention_name>
    <description>CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells</description>
    <arm_group_label>volunteer</arm_group_label>
    <other_name>Senl_19+22</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25mg/㎡ for D-4、D-3 and D-2</description>
    <arm_group_label>volunteer</arm_group_label>
    <other_name>flu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>500mg/㎡ for D-3 and D-2</description>
    <arm_group_label>volunteer</arm_group_label>
    <other_name>ctx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria：&#xD;
&#xD;
          1. The treat history meeting the following criteria:&#xD;
&#xD;
             Recurrence of lymphoma patients with imaging (CT/MRI/PET-CT) detection and&#xD;
             pathological diagnosis, or recurrence including bone marrow morphology relapse and the&#xD;
             MRD recurrence of myeloma patients or leukemia patients, after chemotherapy or stem&#xD;
             cell transplantation; Can't get complete remission (including MRD positive) after more&#xD;
             than twice repeated chemotherapy of incipient lymphoma, myeloma or leukemia patients;&#xD;
             One or twice chemotherapy cannot get remission again (including MRD positive), but not&#xD;
             suitable for chemotherapy of incipient lymphoma, myeloma or leukemia patients.&#xD;
&#xD;
          2. There is a measurable lesions before treatment at least;&#xD;
&#xD;
          3. ECOG score≤2;&#xD;
&#xD;
          4. To be aged 1 to 18 years;&#xD;
&#xD;
          5. More than a month lifetime from the consent signing date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious cardiac insufficiency, left ventricular ejection fraction&lt;50%;&#xD;
&#xD;
          2. Has a history of severe pulmonary function damaging;&#xD;
&#xD;
          3. Merging other progressing malignant tumor;&#xD;
&#xD;
          4. Merging uncontrolled infection;&#xD;
&#xD;
          5. Merging the metabolic diseases (except diabetes);&#xD;
&#xD;
          6. Merging severe autoimmune diseases or immunodeficiency disease;&#xD;
&#xD;
          7. Patients with active hepatitis B or hepatitis C;&#xD;
&#xD;
          8. Patients with HIV infection;&#xD;
&#xD;
          9. Has a history of serious allergies on Biological products (including antibiotics);&#xD;
&#xD;
         10. Has acute GvHD on allogeneic hematopoietic stem cell transplantation patients after&#xD;
             stopping immunosuppressants a month;&#xD;
&#xD;
         11. Any situation that would increase dangerousness of subjects or disturb the outcome of&#xD;
             the clinical study according to the researcher's evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Luo, PhD&amp;MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianqiang Li, PhD&amp;MD</last_name>
    <phone>+8631189928689</phone>
    <email>limmune@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>No.2 Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianqiang Li, PhD &amp; MD</last_name>
      <phone>+86311-89928689</phone>
      <email>limmune@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianmin Luo, PhD &amp; MD</last_name>
      <phone>+86311-66002304</phone>
    </contact_backup>
    <investigator>
      <last_name>Jianmin Luo, PhD &amp; MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

